Vitamin B3 Therapy Reverses Deadly Genetic Disease in Mice | News-Medical.net
Scientists are rethinking how to approach the treatment of rare and devastating genetic diseases, shifting focus from identifying cures for specific illnesses to exploring whether readily available vitamins can alleviate symptoms and extend life expectancy. This novel approach, pioneered by researchers at the Gladstone Institutes, has yielded promising results in the fight against NAXD deficiency, a fatal childhood disorder.
Traditionally, the search for treatments begins with a disease and then attempts to pinpoint a therapeutic target. The Gladstone team reversed this process, starting with vitamins and systematically screening for genetic conditions that might respond to supplementation. Their work, published in Cell, revealed that high-dose vitamin B3 (niacin) dramatically improved outcomes in a mouse model of NAXD deficiency, a disease that typically leads to death within the first few months of life.
“Our goal is to revisit classical vitamin biology with causal and rigorous frameworks,” explains Gladstone Investigator Isha Jain, PhD, senior author of the study. “Rather than randomly supplementing vitamins, we’re using modern genetics to systematically identify which diseases can be treated with which vitamin.”
A Return to the Roots of Vitamin Research
The power of vitamins to combat disease isn’t a new discovery. In the early 20th century, identifying vitamins as cures for conditions like scurvy and beriberi revolutionized medicine and earned researchers Nobel Prizes. However, the widespread availability of inexpensive vitamin supplements has, in recent years, led to a more casual approach to their use, often without strong scientific backing. Dr. Jain believes there’s significant untapped potential for targeted vitamin therapies.
Her lab developed a unique screening process. Using CRISPR gene editing technology, they removed specific genes from human cells, effectively mimicking various genetic conditions. They then tested whether the survival rate of these cells improved when exposed to high concentrations of different vitamins. This allowed them to identify potential vitamin treatments for a range of genetic diseases.
“Each cell represented a different genetic condition that can affect humans,” says Skyler Blume, a research associate in Dr. Jain’s lab and co-first author of the study. “We asked: if we have a vitamin as a potential therapy, which of these genetic conditions could it treat?”
The screen identified vitamin B3 as a potential treatment for cells lacking a functional NAXD gene. Mutations in the NAXD gene in children cause severe developmental delays and early death. The team’s findings suggested that a simple vitamin supplement could potentially make a significant difference for patients.
Vitamin B3 Restores Cellular Function in NAXD Deficiency
Previous research, particularly in yeast, indicated that a healthy NAXD protein helps repair damaged NADH, a molecule crucial for cellular energy production. When NAXD is mutated, damaged NADH accumulates, depleting the active form and disrupting cellular function, particularly in the brain.
To validate these findings in a more complex system, the researchers created the first mouse model of NAXD deficiency. These mice initially appeared healthy but rapidly deteriorated and died within days. Analysis revealed a buildup of damaged NADH throughout their bodies, along with a deficiency of active NADH and another vital molecule called serine in the brain and skin.
The results of the vitamin B3 therapy were remarkable. Daily injections of high-dose vitamin B3, started immediately after birth, dramatically extended the lifespan of the mice. “The treated mice were indistinguishable from their healthy littermates,” Blume reports.
Untreated mice typically died around five days old, while the vitamin B3-treated mice survived for at least 300 days – the point at which the experiment was concluded. Brain inflammation disappeared and levels of NADH and serine normalized.
Hope for Early Diagnosis and Treatment
These findings offer a glimmer of hope for children diagnosed with NAXD deficiency. While anecdotal reports have suggested that some patients improved with vitamin supplementation, this study provides robust experimental evidence supporting the therapeutic potential of vitamin B3. The study also highlights the critical importance of early diagnosis.
“This tells us that NAXD should be added to newborn screening panels,” Dr. Jain emphasizes. “If we can diagnose children immediately after birth and start therapy, we may be able to save lives.”
Beyond NAXD, the team’s framework has identified dozens of other genetic conditions that may be responsive to vitamin B2 or B3 therapy. Dr. Jain and her colleagues plan to continue screening other vitamins for their potential to treat genetic diseases and explore other cell types that showed improved growth in high-vitamin conditions.
“This framework is completely scalable,” Dr. Jain concludes. “We could potentially identify vitamin therapies for hundreds of genetic diseases. We hope other labs will also apply this framework to other micronutrients, beyond vitamins.”